Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Leena Gandhi, MD, PhD, Dana-Farber Cancer Institute
Videos
How to Handle Patients With PD-L1 >50% Non-Small Cell Lung Cancer
12/13/2022
Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.
Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.
Leena Gandhi, MD, PhD, discusses...
12/13/2022
Oncology
Leena Gandhi, MD, PhD, Dana-Farber Cancer Institute
Videos
How to Handle Patients With PD-L1 >50% Non-Small Cell Lung Cancer
12/13/2022
Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.
Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.
Leena Gandhi, MD, PhD, discusses...
12/13/2022
Oncology
Mark Awad, MD, PhD, Dana-Farber Cancer Institute
Videos
Overcoming Resistance to Checkpoint Inhibitors in Lung Cancer
12/13/2022
Dr Mark Awad reviews his presentation at the 2022 Great Debates and Updates in Lung Cancer meeting in New York which focused on the management of patient resistance to checkpoint inhibitors.
Dr Mark Awad reviews his presentation at the 2022 Great Debates and Updates in Lung Cancer meeting in New York which focused on the management of patient resistance to checkpoint inhibitors.
Dr Mark Awad reviews his...
12/13/2022
Oncology
Lyudmila Bazhenova, MD, Professor of Medicine at the University of California, San Diego, California
Videos
Dabrafenib Plus Trametinib for Patients With BRAF-V600E Mutated Lung Cancer
12/02/2022
Lyudmila Bazhenova, MD, reviews the treatment options for BRAF mutations in lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD, reviews the treatment options for BRAF mutations in lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD, reviews...
12/02/2022
Oncology
Edward Garon, MD, David Geffen School of Medicine - UCLA, Los Angeles, California
Videos
Pembrolizumab Monotherapy for Patients With HighPD-L1 Non-Small Cell Lung Cancer
12/02/2022
Edward Garon, MD, discusses the treatment of patients with non-small cell lung cancer and a PD-L1 expression of ≥50%, a topic he debated at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Edward Garon, MD, discusses the treatment of patients with non-small cell lung cancer and a PD-L1 expression of ≥50%, a topic he debated at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Edward Garon, MD, discusses the...
12/02/2022
Oncology
Lyudmila Bazhenova, MD
Videos
Differentiating Targets and Therapies for Patients With HER2-Mutant Lung Cancer
11/29/2022
Lyudmila Bazhenova, MD, University of California, San Diego, California, discusses the management and treatment of patients with HER2-mutated non-small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung...
Lyudmila Bazhenova, MD, University of California, San Diego, California, discusses the management and treatment of patients with HER2-mutated non-small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung...
Lyudmila Bazhenova, MD,...
11/29/2022
Oncology
Lyudmila Bazhenova, MD
Videos
Targeting and Treating MET-Dependent Lung Cancers
11/18/2022
Lyudmila Bazhenova, MD, discusses targeted therapy for MET-dependent lung cancers, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD, discusses targeted therapy for MET-dependent lung cancers, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD,...
11/18/2022
Oncology
Kristin Higgins, MD
Videos
Current and Emerging Treatments in Small Cell Lung Cancer
11/18/2022
Kristin Higgins, MD, provides an overview on the current and future treatment of small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancers meeting in New York.
Kristin Higgins, MD, provides an overview on the current and future treatment of small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancers meeting in New York.
Kristin Higgins, MD, provides an...
11/18/2022
Oncology
Helena Yu, MD
Videos
EGFR TKIs for Curative Intent Among Patients With Early-Stage Non-Small Cell Lung Cancer
11/15/2022
Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Helena Yu, MD, discusses the...
11/15/2022
Oncology
David Cescon, MD, Princess Margaret Cancer Center
Videos
CDK4/6 Inhibitors Exhibit Similarities in Progression-Free Survival for Metastatic ER-Positive/HER2-Negative Breast Cancer
11/14/2022
David Cescon, MD, PhD, discusses the similarities and differences in CDK4/6 inhibitors for patients with breast cancer, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.
David Cescon, MD, PhD, discusses the similarities and differences in CDK4/6 inhibitors for patients with breast cancer, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.
David Cescon, MD, PhD, discusses...
11/14/2022
Oncology

Advertisement

About

Formerly known as Perspectives in Thoracic Oncology, the lung cancer meeting you know and love is getting a makeover. With an updated name to reflect a more pronounced focus on targeted therapies, biomarker testing and precision medicine, year 25 of this educational gathering is getting practical. Personalized Therapies in Thoracic Oncology will go beyond chemotherapy and focus on the best way to treat your patients when traditional methods aren't cutting it. 

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use